A Potential Functional Cure in Chinese HBeAg-negative Chronic Hepatitis B Patients Treated with Peg-interferon Alpha-2a.

J Clin Transl Hepatol · 2019 · PMC6783682 · PMID 31608217

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

2 In China, surveys conducted in 2006 and 2014 showed a decreasing trend in hepatitis B surface antigen (HBsAg) prevalence after the start of a vaccination program in 1992. 3 However, in 2016, the prevalence of HBsAg was reported to be relatively high, namely 6.0% in men aged 21–49 years in rural China 4 and 6.1% in Northeastern China. 5 Among HBsAg-positive individuals

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.